2 0 1 2 H I V D RUG GU I D E
Side effects
Entry inhibitors Potential drug class side effects
Immune Reconstitution Inflammatory Syndrome (IRIS) may occur as the immune system regains strength; signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is initiated. Report symptoms of illness, such as shingles and TB, to a health care provider.
Fuzeon
Injection site reactions (ISRs), pneumonia, diarrhea, nausea, and fatigue. Hypersensitivity reactions are possible.
(enfuvirtide, T-20, ENF)
Selzentry (maraviroc, or MVC)
Cough, fever, cold, rash, muscle and joint pain, stomach pain, dizziness, liver toxicity, allergic reaction, low blood pressure, and possible increased risk of infections and cancer.
Single-tablet regimens (STRs) Atripla (efavirenz / emtricitabine / tenofovir)
Complera (rilpivirine / emtricitabine / tenofovir)
Photo: Joshua Thorne
The “Quad� (elvitegravir / cobicistat / emtricitabine / tenofovir) (investigational drug)
See Sustiva and Truvada (Emtriva and Viread). Atripla dose cannot be adjusted for people with kidney problems. Nausea, diarrhea, rash, insomnia, abnormal dreams, and depressive disorders. See Edurant and Truvada (Emtriva and Viread). Complera dose cannot be adjusted for people with kidney problems. Insomnia, headache, nausea, dizziness, rash, abnormal dreams, and depressive disorders. See elvitegravir, cobicistat, and Truvada (Emtriva and Viread). The Quad dose cannot be adjusted for people with kidney problems. Nausea, diarrhea, and rash. Available data is limited due to investigational status at press time.
PK enhancer Cobicistat (or COBI) (investigational drug)
positivelyaware.com/drugguide
Seen in clinical study: diarrhea, nausea, lipid elevations (increases in cholesterol and triglycerides), creatine kinase, red blood cells in urine, increased serum creatinine, and decreased estimated glomerular filtration rate (e-GFR). Available data is limited due to investigational status at press time.
M a r c h +A p r i l 2 0 1 2
73